|
The board of Zydus Lifesciences is scheduled to meeting on Friday, 9 February 2024. to consider buyback.
The company's board will also consider Q3FY24 result on Friday, 9 February 2024.
Zydus Lifesciences is a discovery-driven, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies.
The company’s consolidated net profit surged 53.2% to Rs 800.7 crore on 9.1% increase in revenue from operations to Rs 4,368.8 crore in Q2 FY24 over Q2 FY23.
|